In 2021, deaths from drug overdose exceeded 100 000 in the US, a reflection of the rapid increase in the prevalence of illicit synthetic opioids, such as fentanyl and its analogues. Mortality related to fentanyl has surpassed that from prescription opioids and heroin; in 2021, it accounted for 82% of opioid overdose deaths.1 As the opioid epidemic evolves, policies and guidelines should adapt to this new reality. Patients require access to evidence-based and equitable treatment without unnecessary barriers to receiving care.
Incze MA, Kelley AT, Johnson K. Reexamining Medicaid Patient Review and Restriction Programs Amid the Evolving Opioid Epidemic. JAMA Intern Med. 2022;182(8):789–790. doi:10.1001/jamainternmed.2022.1952
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.